Development and Scale-up of a Microsphere Protein Delivery System
The DOI matches its Crossref record.
Abstract
This paper reviews the development path for the ProLease injectable microsphere delivery system for proteins using human growth hormone as an example. The process consists of four stages, the selection of a lead formulation for clinical testing, the preclinical evaluation of the lead formulation including toxicology and stability studies, the manufacture of phase I clinical supplies, and the scale-up for phase II and phase III clinical trials. The approaches used to overcome obstacles during each stage are summarized including ways of stabilizing the protein, obtaining desirable release kinetics, and manufacturing sterile batches for clinical testing. Stability, release, toxicology, and scale-up results for ProLease recombinant human growth hormone (rhGH) are given. The phase I clinical data show that bioactive rhGH was released for about 1 month in humans. This work shows that processes and procedures have been developed that enable the production of microsphere sustained release formulations for proteins suitable for clinical trails and commercialization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Polymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633
Freitas, S., Merkle, H. P., & Gander, B. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.015 · Cited by 923
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles
Wischke, C., & Schwendeman, S. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.042 · Cited by 790
Fu, K., Pack, D. W., Klibanov, A. M., & Langer, R. (2000) · Pharmaceutical Research · doi:10.1023/a:1007582911958 · Cited by 764
Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles
van de Weert, M., Hennink, W. E., & Jiskoot, W. (2000) · Pharmaceutical Research · doi:10.1023/a:1026498209874 · Cited by 708
Control of encapsulation efficiency and initial burst in polymeric microparticle systems
Yeo, Y., & Park, K. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02980037 · Cited by 567
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 520
JIANG, W., GUPTA, R., DESHPANDE, M., & SCHWENDEMAN, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.003 · Cited by 478
Issues in long-term protein delivery using biodegradable microparticles
Ye, M., Kim, S., & Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.011 · Cited by 386
Ziaee, A., Albadarin, A. B., Padrela, L., Femmer, T., O'Reilly, E., & Walker, G. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.10.026 · Cited by 366
Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions
Berkland, C., Kim, K. (., & Pack, D. W. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00289-9 · Cited by 336
Spray Drying of Biopharmaceuticals: Stability and Process Considerations
Ameri, M., & Maa, Y.-F. (2006) · Drying Technology · doi:10.1080/03602550600685275 · Cited by 300
Davies, O. R., Lewis, A. L., Whitaker, M. J., Tai, H., Shakesheff, K. M., & Howdle, S. M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.12.001 · Cited by 299
Protein stability in controlled-release systems
Fu, K., Klibanov, A. M., & Langer, R. (2000) · Nature Biotechnology · doi:10.1038/71875 · Cited by 258
FREITAS, S., RUDOLF, B., MERKLE, H., & GANDER, B. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.004 · Cited by 36
Metadata
- Authors
- Tracy, M. A.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 1998-02-06
- Volume
- 14
- Issue
- 1
- Pages
- 108-115
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2119791875
- Cited by
- 122
- References
- 0
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.